Biologic product identification and US pharmacovigilance in the biosimilars era

被引：14

作者：

Felix, Thomas ^{[1
]}

Johansson, Torbjoern T. ^{[2
]}

Colliatie, Jodi A. ^{[3
]}

Goldberg, Michael R. ^{[3
]}

Fox, Andrew R. ^{[4
]}

机构：

[1] Amgen Inc, Washington, DC USA

[2] Amgen Inc, Zug, Switzerland

[3] Amgen Inc, Thousand Oaks, CA 91320 USA

[4] Onyx Pharmaceut UK Ltd, Birmingham, W Midlands, England

来源：

NATURE BIOTECHNOLOGY | 2014年 / 32卷 / 02期

关键词：

D O I：

10.1038/nbt.2823

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

引用

页码：128 / 130

页数：3

共 9 条

[1]

[Anonymous], 2012, GUID IND SCI CONS DE

[2]

Booz Allen Hamilton, 2010, EVALUATION POTENTIAL

[3]

Evaluating the Completeness and Accuracy of MedWatch Data [J].

Getz, Kenneth A. ;

Stergiopoulos, Stella ;

Kaitin, Kenneth I. .

AMERICAN JOURNAL OF THERAPEUTICS, 2014, 21 (06) :442-446

[4]

Government Accountability Office, 2010, FOOD DRUG ADM RESP H

[5]

IMS Health, 2011, SHAP BIOS OPP GLOB P

[6]

Olson K., 2012, ALLIANCE SAFE BIOL M

[7]

US Food and Drug Administration, 2012, 125418ORIG1S000 US F

[8]

US Food and Drug Administration, 2012, PROP NAM REV

[9]

Vermeer N., 2012, 28 INT C PHARM THER

← 1 →